Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias

Alzheimer's and Dementia

Volumn 10, Issue 4, 2014, Pages 448-455.e2

  Herbert, Megan K ^a   Aerts, Marjolein B ^a   Kuiperij, H Bea ^a   Claassen, Jurgen A H R ^a   Spies, Petra E ^a   Esselink, Rianne A J ^a   Bloem, Bastiaan R ^a   Verbeek, Marcel M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; CSF biomarkers; Dementia with Lewy bodies; Differential diagnosis; Frontotemporal dementia; Vascular dementia

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ANALYTICAL PARAMETERS; ARTICLE; CEREBROSPINAL FLUID; COGNITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; LEWY BODY DISEASE; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; FEMALE; HUMANS; LEWY BODY DISEASE; LOGISTIC MODELS; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 84903710063     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.05.1775     Document Type: Article

References (51)

1. K. Christensen, G. Doblhammer, R. Rau, and J.W. Vaupel Ageing populations: the challenges ahead Lancet 374 2009 1196 1208
2. C. Brayne, B.C.M. Stephan, and F.E. Matthews A European perspective on population studies of dementia Alzheimer Dement 7 2011 3 9
3. A.M. Lobo, L.J.P. Launer, L.M. Fratiglioni, K. Andersen, A. Di Carlo, and M.M. Breteler et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts Neurology 54 Suppl. 5 2000 S4 S9
4. C.P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, and M. Ganguli et al. Global prevalence of dementia: a Delphi consensus study Lancet 366 2005 2112 2117
5. W.W. Barker, C.A. Luis, A. Kashuba, M. Luis, D.G. Harwood, and D. Loewenstein et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank Alzheimer Dis Assoc Disord 16 2002 203 212
6. H. Brunnström, L. Gustafson, U. Passant, and E. Englund Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports Arch Gerontol Geriatr 49 2009 146 149
7. S.S. Shaik, and A.R. Varma Differentiating the dementias: a neurological approach Prog Neurol Psychiatry 16 2012 11 18
8. J.A. Schneider, Z. Arvanitakis, W. Bang, and D.A. Bennett Mixed brain pathologies account for most dementia cases in community-dwelling older persons Neurology 69 2007 2197 2204
9. M.F. Mendez, and A. Lipton Emergent neuroleptic hypersensitivity as a herald of presenile dementia J Neuropsychiatry Clin Neurosci 13 2001 347 356
10. D. Aarsland, R. Perry, J.P. Larsen, I.G. McKeith, J.T. O'Brien, and E.K. Perry et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias J Clin Psychiatry 66 2005 633 637
11. I. McKeith, T. Del Ser, P. Spano, M. Emre, K. Wesnes, and R. Anand et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study Lancet 356 2000 2031 2036
12. M. Rolinski, C. Fox, I. Maidment, and R. McShane Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease Cochrane Database Syst Rev 3 2012 CD006504
13. M.B. Aerts, R.A.J. Esselink, J.A.H.R. Claassen, W.F. Abdo, B.R. Bloem, and M.M. Verbeek CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease J Alzheimers Dis 27 2011 377 384
14. D.M. Mann, J. Lincoln, P.O. Yates, J.E. Stamp, and S. Toper Changes in the monoamine containing neurones of the human CNS in senile dementia Br J Psychiatry 136 1980 533 541
15. K. Ohaea, N. Kondo, and O. Kenshiro Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease Prog Neuropsychopharmacol Biol Psychiatry 22 1998 311 317
16. P. Szot, S.S. White, J.L. Greenup, J.B. Leverenz, E.R. Peskind, and M.A. Raskind Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies J Neurosci 26 2006 467 478
17. E. Iseki, M. Kato, W. Marui, K. Uéda, and K. Kosaka A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies J Neurol Sci 185 2001 129 134
18. M. Kawakami, and T. Itoh Effects of idebenone on monoamine metabolites in cerebrospinal fluid of patients with cerebrovascular dementia Arch Gerontol Geriatr 8 1989 343 353
19. M. Sjögren, L. Minthon, U. Passant, K. Blennow, and A. Wallin Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease Neurobiol Aging 19 1998 379 384
20. A. Wallin, K. Blennow, A. Edman, and J.E. Månsson Decreased lumbar cerebrospinal fluid levels of monoamine metabolites in vascular dementia Int Psychogeriatr 8 1996 425 436
21. E. Martignoni, G. Bono, F. Blandini, E. Sinforiani, P. Merlo, and G. Nappi Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl J Neural Transm 3 1991 15 25
22. M.A. Raskind, E.R. Peskind, J.B. Halter, and D.C. Jimerson Norepinephrine and MHPG levels in CSF and plasma in Alzheimer's disease Arch Gen Psychiatry 41 1984 343 346
23. I.G. McKeith Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop J Alzheimers Dis 9 2006 417 423
24. G.M.D. McKhann, D.M.D. Drachman, M.M.D. Folstein, R.M.D. Katzman, D.M.D. Price, and E.M.M.D. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939 944
25. G.C.M. Roman, T.K.M. Tatemichi, T.M. Erkinjuntti, J.L. Cummings, J.C. Masdeu, and J.H. Garcia et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop Neurology 43 1993 250 260
26. A. Brun, E. Englund, L. Gustafson, U. Passant, D.M. Mann, and D. Neary et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups J Neurol Neurosurg Psychiatry 57 1994 416 418
27. M.L. Gorno-Tempini, A.E. Hillis, S. Weintraub, A. Kertesz, M. Mendez, and S.F. Cappa et al. Classification of primary progressive aphasia and its variants Neurology 76 2011 1006 1014
28. G.M. McKhann, M.S. Albert, M. Grossman, B. Miller, D. Dickson, and J.Q. Trojanowski Clinical and pathological diagnosis of frontotemporal dementia Arch Neurol 58 2001 1803 1809
29. A. Kertesz, M. Blaeir, P. McMonagle, and D.G. Munoz The diagnosis and course of frontotemporal dementia Alzheimer Disease Assoc Disord 21 2007 155 163
30. D. Neary, J. Snowden, and D. Mann Frontotemporal dementia Lancet Neurol 4 2004 771 780
31. M.M. Mesulam Primary progressive aphasia Ann Neurol 49 2001 425 432
32. C. Bräutigam, R.A. Wevers, R.J.T. Jansen, J.A.M. Smeitink, J.F. de Rijk-van Andel, and F.J.M. Gabreëls et al. Biochemical hallmarks of tyrosine hydroxylase deficiency Clin Chem 44 1998 1897 1904
33. W.F. Abdo, D. De Jong, J.C.M. Hendriks, M.W.I.M. Horstink, B.P.H. Kramer, and B.R. Bloem et al. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease Mov Disord 19 2004 571 579
34. M.F. Weiner, R.C. Risser, C.M. Cullum, L. Honig, C. White, and S. Speciale et al. Alzheimer's disease and its Lewy body variant: a clinical analysis of postmortem verified cases Am J Psychiatry 153 1996 1269 1273
35. J.B. Leverenz, M.A. Miller, D.J. Dobie, E.R. Peskind, and M.A. Raskind Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies Neurobiol Aging 22 2001 555 561
36. C. Czech, P. Berndt, K. Busch, O. Schmitz, J. Wiemer, and V. Most et al. Metabolite profiling of alzheimer's disease cerebrospinal fluid PLoS One 7 2012 e31501
37. M.A. Raskind, E.R. Peskind, C. Holmes, and D.S. Goldstein Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease Biol Psychiatry 46 1999 756 765
38. G.S. Watson, T. Bernhardt, M.A. Reger, B.A. Cholerton, L.D. Baker, and E.R. Peskind et al. Insulin effects on CSF norepinephrine and cognition in Alzheimer's disease Neurobiol Aging 27 2006 38 41
39. P. Formichi, C. Battisti, E. Radi, and A. Federico Cerebrospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease J Cell Physiol 208 2006 39 46
40. ox% in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia Int J Alzheimers Dis 2010 2010
41. N.S.M. Schoonenboom, F.E. Reesink, N.A. Verwey, M.I. Kester, C.E. Teunissen, and P.M. van de Ven et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort Neurology 78 2012 47 54
42. B. Mollenhauer, L. Cepek, M. Bibl, J. Wiltfang, W.J. Schulz-Schaeffer, and B. Ciesielczyk et al. Tau protein, Aβ42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies Dement Geriatr Cogn Disord 19 2005 164 170
43. N. Mattsson, E. Rosén, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers Neurology 78 2012 468 476
44. Y. Yang, and H.P. Schmitt Frontotemporal dementia: evidence for impairment of ascending serotoninergic but not noradrenergic innervation Acta Neuropathol 101 2001 256 270
45. M. Haglund, M. Sjöbeck, and E. Englund Locus coeruleus degeneration is ubiquitous in Alzheimer's disease: possible implications for diagnosis and treatment Neuropathology 26 2006 528 532
46. E. Ratnavalli, C. Brayne, K. Dawson, and J.R. Hodges The prevalence of frontotemporal dementia Neurology 58 2002 1615 1621
47. S.M. Rosso, L.D. Kaat, T. Baks, M. Joosse, I. de Koning, and Y. Pijnenburg et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study Brain 126 2003 2016 2022
48. D.J. Irwin, C.T. McMillan, J.B. Toledo, S.E. Arnold, S.M. Shaw, and L. Wang et al. Comparison of Cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms Arch Neurol 69 2012 1018 1025
49. E. Kapaki, G.P. Paraskevas, I. Zalonis, and C. Zournals CSF tau protein and β-amyloid (1-42) in Alzheimer's diseases diagnosis: discrimination from normal ageing and other dementias in the Greek population Eur J Neurol 10 2003 119 128
50. M.A. Smach, B. Charfeddine, B. Othman, T. Lammouchi, H. Dridi, and S. Nafati et al. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease Eur Neurol 62 2009 349 355
51. N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, and B. Winblad et al. Evaluation of CSF tau and CSF Abeta42 as diagnostic markers for Alzheimer disease in clinical practice Arch Neurol 58 2001 373 379